Precision Medicine in NSCLC: Real-World Applications of Testing & Treatment for the Managed Care Pharmacist
The last decade has seen expanded use of biomarker testing in non-small cell lung cancer (NSCLC) and a growing field of targeted therapies that have transformed the treatment landscape of advanced disease. The pace of changes in the field makes it difficult to translate the latest trial data and guideline recommendations into real-world practice. Gaps in appropriate testing or treatment can dramatically diminish survival gains seen in major cancer centers.
Managed care and specialty pharmacists will work through case scenarios involving the latest guideline recommendations for biomarker testing, currently available targeted therapies, and approaches to consider when balancing the cost and value of precision medicine.
Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
This activity is designed to meet the educational needs of pharmacy directors, pharmacists, physicians, medical directors, and other managed care professionals attending the Virtual AMCP Nexus 2020.
- Review the most recent testing guidelines for non-small cell lung cancer (NSCLC), including clinically relevant biomarkers, recommended testing modalities, and implications for currently available and evolving treatments.
- Examine targeted therapies currently approved for NSCLC and appraise biomarker-driven approaches to selection and sequencing of therapy.
- Using real-world cases, consider approaches for managed care pharmacists to use when balancing costs and values of precision medicine testing and treatments.
Josiah D. Land, PharmD, BCOP
Clinical Pharmacy Specialist
Thoracic Medical Oncology Team
Memorial Sloan Kettering Cancer Center
New York, New York
Originally from Lake Charles, Louisiana, Dr. Josiah Land received his BS in Biology from McNeese State University in Lake Charles and his PharmD from the University of Louisiana at Monroe in Monroe, LA. After pharmacy school, he completed a PGY1 Pharmacy Residency at The University of Texas MD Anderson Cancer Center in Houston, TX followed by a PGY2 Oncology Pharmacy Residency at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Land is currently the Clinical Pharmacy Specialist for the Thoracic Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York, NY. He is a Board Certified Oncology Pharmacist (BCOP) through the Board of Pharmacy Specialties (BPS).
Val Adams, PharmD, FCCP, BCOP
University of Kentucky College of Pharmacy
Markey Cancer Center
Dr. Val Adams is an Associate Professor in the Department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center where he has a clinical practice site. He co-chairs the protocol review and monitoring committee for the NCI Designated Markey Cancer Center. As the Director of the hematology/oncology residency program, he has trained 40 PGY2 oncology residents and maintains an active research program. He has trained two post-doctoral fellows, been the thesis advisor for four masters students, and served on 20 PhD dissertation student committees serving as advisor or co-advisor for 7 of them. He received his BS in Pharmacy from the University of Utah and received his Doctor of Pharmacy from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology/oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship, he joined the University of Kentucky faculty in 1996.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations.
A commercial interest is defined as any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Joan B. Fowler, PharmD, BCPS—has no relevant financial relationships to disclose in relation to the content of this activity.
Josiah D. Land, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
Val R. Adams, PharmD, FCCP, BCOP—has disclosed that he is a consultant for Amgen.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit JA0007101-0000-20-010-L01-P.